HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine.
暂无分享,去创建一个
[1] M. Sanguinetti,et al. Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides. , 1996, Circulation research.
[2] J. R. Clay,et al. A quantitative description of the E-4031-sensitive repolarization current in rabbit ventricular myocytes. , 1995, Biophysical journal.
[3] G. Robertson,et al. HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.
[4] Y Rudy,et al. Two components of the delayed rectifier K+ current in ventricular myocytes of the guinea pig type. Theoretical formulation and their role in repolarization. , 1995, Circulation research.
[5] M. Sanguinetti,et al. A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.
[6] C. Berul,et al. Regulation of potassium channels by nonsedating antihistamines. , 1995, Circulation.
[7] J. Chant,et al. GTPase cascades choreographing cellular behavior: Movement, morphogenesis, and more , 1995, Cell.
[8] E. Green,et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.
[9] J. Lynch,et al. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. , 1995, Circulation research.
[10] W. Crumb,et al. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: possible mechanism for terfenadine-associated cardiotoxicity. , 1995, Molecular pharmacology.
[11] T. Cyr,et al. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[12] C. Luo,et al. A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes. , 1994, Circulation research.
[13] A. Brown,et al. Specification of pore properties by the carboxyl terminus of inwardly rectifying K+ channels. , 1994, Science.
[14] J. Warmke,et al. A family of potassium channel genes related to eag in Drosophila and mammals. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[15] J. Hedges,et al. Possible interactions with terfenadine or astemizole. , 1994, The Western journal of medicine.
[16] P. Spooner. Ion channels in the cardiovascular system : function and dysfunction , 1994 .
[17] A. Brown,et al. Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. , 1993, Molecular pharmacology.
[18] S Nattel,et al. Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. , 1993, Circulation research.
[19] T. Wenger,et al. Terfenadine Alters Action Potentials in Isolated Canine Purkinje Fibers More Than Acrivastine , 1993, Journal of cardiovascular pharmacology.
[20] B. Fermini,et al. Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. , 1993, Circulation research.
[21] Y Chen,et al. Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.
[22] D. Wortham,et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.
[23] S. Roberds,et al. Molecular Biology of the Voltage‐Gated Potassium Channels of the Cardiovascular System , 1993, Journal of cardiovascular electrophysiology.
[24] P. Lévy,et al. Torsades de Pointes after treatment with terfenadine and ketoconazole. , 1992, European heart journal.
[25] K. Chinn,et al. Contribution of delayed rectifier and inward rectifier to repolarization of the action potential: pharmacologic separation. , 1992, Journal of cardiovascular pharmacology.
[26] D. Roden,et al. Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias. , 1992, The American journal of cardiology.
[27] D. Roden,et al. Molecular cloning and characterization of two voltage‐gated K+ channel cDNAs from human ventricle , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[28] C. L. Ferguson,et al. Torsades de pointes occurring in association with terfenadine use. , 1990, JAMA.
[29] D. Roden,et al. Time-dependent outward current in guinea pig ventricular myocytes. Gating kinetics of the delayed rectifier , 1990, The Journal of general physiology.
[30] M. Sanguinetti,et al. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents , 1990, The Journal of general physiology.
[31] R. Stein,et al. Cloning and expression of the delayed-rectifier IsK channel from neonatal rat heart and diethylstilbestrol-primed rat uterus. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[32] S. Nakanishi,et al. Molecular cloning and sequence analysis of human genomic DNA encoding a novel membrane protein which exhibits a slowly activating potassium channel activity. , 1989, Biochemical and biophysical research communications.
[33] V. Harindra,et al. Cardiotoxic effect with convulsions in terfenadine overdose. , 1989, BMJ.
[34] S. Nakanishi,et al. Cloning of a membrane protein that induces a slow voltage-gated potassium current. , 1988, Science.
[35] R. Heel,et al. Terfenadine. A review of its pharmacodynamic properties and therapeutic efficacy. , 1985, Drugs.
[36] D. Noble,et al. Outward membrane currents activated in the plateau range of potentials in cardiac Purkinje fibres , 1969, The Journal of physiology.